Specific Substances: Hydralazine hydrochloride
Nomination Date: 06/02/1997
Nominator: Private Individual
Rationale: Hydralazine hydrochloride is used in various antihypertensive drug formulations for which several million prescriptions are written annually. It is suspected of being a carcinogen based on mutagenicity data and positive mutagenicity and carcinogenicity data in animals for structurally related compounds. There is a lack of complete and adequate 2-year bioassay data for hydralazine hydrochloride.
NTP Principles: not specified
Status: In Review/Pending
Agents and Status
The following information relates to the specific agent and may include history from earlier or later nominations for this same agent.
Agent Name: Hydralazine hydrochloride